TMPRSS9: Transmembrane Serine Protease 9
A type II transmembrane serine protease with potential roles in cancer and cellular signaling.
Gene Information Card
| Symbol | TMPRSS9 |
|---|---|
| Full Name | Transmembrane Serine Protease 9 |
| Gene Type | protein-coding |
| Chromosomal Location | 19p13.3 |
| NCBI Gene ID | 360200 ncbi.nlm.nih.gov/gene/360200 |
| Ensembl ID | ENSG00000178297 |
| UniProt ID | Q7Z410 |
| OMIM ID | 610911 |
| HGNC ID | 24079 |
| Aliases | MSPL, polyserase-1, TMPRSS9A, TMPRSS9B |
Description
TMPRSS9 (Transmembrane Serine Protease 9) encodes a type II transmembrane serine protease that contains multiple serine protease domains. The protein is involved in proteolytic processing of extracellular matrix components and may play a role in tumor progression and metastasis. Alternative splicing generates multiple isoforms, including a secreted form (polyserase-1) and a membrane-bound form (MSPL).
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Prostate Cancer | Overexpression of TMPRSS9 may promote invasion and metastasis through extracellular matrix degradation. | NCBI Gene, PubMed |
| Colorectal Cancer | Altered expression levels observed in tumor tissues; potential biomarker. | NCBI Gene, PubMed |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Prostate | 2.1 | Low |
| Colon | 1.8 | Low |
| Kidney | 1.5 | Low |
| Liver | 0.9 | Not detected |
| Lung | 0.7 | Not detected |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| LNCaP (prostate cancer) | 3.2 | Moderate expression |
| HT-29 (colorectal cancer) | 2.5 | Low expression |
| HEK293 (embryonic kidney) | 1.1 | Not detected |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1234G>A (p.Gly412Arg) | missense | <0.1% | Unknown |
| c.567_568del (p.Leu190fs) | frameshift | <0.1% | Loss of function |
Mutation functional classification
Loss of Function (LOF)
Frameshift mutations leading to premature stop codons are predicted to result in loss of proteolytic activity.
Gain of Function (GOF)
No gain-of-function mutations have been reported in TMPRSS9.
Dominant Negative (DN)
No dominant-negative mutations have been characterized for TMPRSS9.
View complete mutation data：
Gene Ontology (GO)
| • serine-type endopeptidase activity | • proteolysis |
| • extracellular matrix disassembly | • membrane |
Pathways
• Proteolysis
• Extracellular matrix organization
Protein Summary
TMPRSS9 is a 1045-amino acid type II transmembrane serine protease with a short cytoplasmic tail, a transmembrane domain, and two tandem serine protease domains (S1 and S2). The protein is synthesized as a zymogen and activated by proteolytic cleavage. It is capable of degrading extracellular matrix components such as fibronectin and gelatin, suggesting a role in tissue remodeling and cancer invasion.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| TMPRSS9 Knockout HEK293 Cell Line | EDJ-KQ10818 | Human | 360200 | Details Get a Quote |
| TMPRSS9 Knockout HeLa Cell Line | EDJ-KQ59885 | Human | 360200 | Details Get a Quote |
| TMPRSS9 Knockout A-549 Cell Line | EDJ-KQ68348 | Human | 360200 | Details Get a Quote |
| TMPRSS9 Knockout HCT 116 Cell Line | EDJ-KQ76724 | Human | 360200 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
